Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 01-2014 | 12-2013 | 10-2013 | 09-2013 | 07-2013 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 47 | N/A | 52 | N/A | 37 |
| Receivables | 35 | N/A | 25 | N/A | 29 |
| Other current assets | 8 | 0 | 13 | 0 | 17 |
| TOTAL | $104 | $N/A | $106 | $N/A | $87 |
| Non-Current Assets | |||||
| PPE Net | 37 | N/A | 40 | N/A | 42 |
| TOTAL | $37 | $N/A | $40 | $N/A | $42 |
| Total Assets | $141 | $N/A | $146 | $N/A | $129 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 13 | 2 | 15 | 0 | 11 |
| Accrued Expenses | N/A | 180 | N/A | N/A | N/A |
| TOTAL | $54 | $182 | $62 | $N/A | $64 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $54 | $182 | $62 | $N/A | $64 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 14 | N/A | N/A | N/A | 13 |
| Common Shares | 4 | 1 | 4 | N/A | 3 |
| Retained earnings | 0 | -183 | -3 | N/A | 2 |
| TOTAL | $87 | $-182 | $83 | $N/A | $65 |
| Total Liabilities And Equity | $141 | $0 | $146 | $0 | $129 |